Formatech has selected KAI Pharmaceuticals’ KAI-4169 compound as the second clinical candidate to receive “free” manufacturing services under its Fillanthropy Program. KAI-4169 is being evaluated for the treatment of secondary hyperparathyroidism. Under the program, Formatech will donate the services required to aseptically fill and finish one lot of the drug product for use in KAI’s upcoming trials.

Formatech plans to complete the production run of KAI-4169 in 1Q10. “We’re excited to have the opportunity to work with KAI on this program,” said Jeffrey Bernard, Formatech’s director of business development. “KAI’s technology for developing selective Protein C Kinase inhibitors is very promising and has the potential to be very impactful in the treatment of a number of diseases. We’re pleased to donate our services for this program and we wish KAI success with this candidate.”

“It is an honor to receive this award from Formatech as part of their philanthropic effort,” said Steve James, president and chief executive officer of KAI Pharmaceuticals. “We appreciate Formatech’s commitment to this program. Secondary hyperparathyroidism is leading cause of morbidity and mortality in patients with chronic kidney disease. This fill will help support our program and we look forward to exciting results in the year ahead.”

News from our sister sites